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Fertility-sparing treatment in female genital 
cancer and breast cancer
Leczenie nowotworów złośliwych żeńskiego narządu rodnego i piersi 
z zachowaniem możliwości prokreacji
Postponed motherhood is the reason why many women are diagnosed with cancer before they make the decision 
to conceive a child, but only a small number o f the affected patients will receive any information about treatment- 
related infertility.
As far as female genital cancer is concerned, cervical cancer continues to be the most frequently diagnosed ma­
lignancy in women o f childbearing age, In its early stages, it can be treated with surgical procedures which spare 
the genitals, i,e, surgical conization and vaginal radical trachelectomy with laparoscopic lymphadenectomy. The 
advantages o f these procedures have been observed in our experience, Also, a successful conservative 6-month 
treatment o f endometrial cancer limited to the mucous membrane with progestagens following curettage o f the 
uterine cavity has been reported in the literature,
This paper also presents our own experience with fertility-sparing surgical treatment o f ovarian cancer with border­
line malignancy and invasive IA stage, Breast cancer affects over 7% o f all cancer patients under the age o f 40, 
Pregnancy after breast cancer treatment has been shown to develop properly and both, pregnancy and breast­
feeding have no influence on cancer relapse, Protective shields for the adnexa or relocation o f the ovaries should 
be used during radiotherapy in patients who wish to preserve their fertility, In case o f chemotherapy, application o f 
GnRH analogs has shown promising results in preservation o f the ovarian function, Also, the development o f new  
assisted reproductive technology has offered an increasing number o f alternatives for young cancer patients who 
wish to preserve their fertility,
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Streszczenie
Przesuwanie macierzyństwa na późniejsze lata sprawia, że u wielu kobiet wystąpienie choroby nowotworowej 
często wyprzedza decyzję o macierzyństwie, Niestety tylko część pacjentek z rozpoznanym nowotworem złośliwym  
zlokalizowanym nierzadko poza narządem rodnym otrzymuje informację na temat możliwości niepłodności 
związanej z  leczeniem procesu nowotworowego,
Wśród nowotworów złośliwych narządu rodnego jednym z najczęstszych występujących w  okresie zdolności do 
prokreacji jest rak szyjki macicy. Jego wczesne postacie można leczyć chirurgicznie oszczędzając narząd rodny 
tj, wykonując chirurgiczną konizacją lub radykalną pochwową trachelektomię z laparoskopową limfadenektomią, 
O wartości takiego postępowania świadczą nasze własne doświadczenia, Istnieją także doniesienia 
o zachowawczym leczeniu progestagenami w  sytuacji raka endometrium ograniczonego do błony śluzowej, po 
uprzednim wyłyżeczkowaniu jam y macicy.
W pracy przedstawiono doświadczenia (również własne) w  leczeniu chirurgicznym raka jajnika o granicznej 
złośliwości i w  stopniu zaawansowania klinicznego IA zachowując prokreacje, Około 7% raka piersi dotyczy kobiet 
poniżej 40 roku życia, Wskazano, że ciąża po leczeniu raka piersi rozwija się prawidłowo, Podobnie, zarówno ciąża 
ja k  i karmienie zdrową piersią nie mają wpływu na wzrost ryzyka wznowy raka piersi, Przy stosowaniu radioterapii 
w  zależności od lokalizacji nowotworu u kobiet pragnących zachować płodność należy stosować osłony na przydatki 
lub wykonać relokację jajników, W razie konieczności stosowania chemioterapii obiecujące wyniki w  oszczędzeniu 
funkcji rozrodczych ja jników daje zastosowanie w  trakcie je j trwania analogów GnRH, Coraz częściej również w  tych 
trudnych sytuacjach bezpieczne rozwiązania oferują nowe techniki medycyny wspomaganego rozrodu,
Słowa kluczowe: rak szyjki macicy rak endometrium / rak jajnika rak piersi 
zachowanie płodności /
Delayed motherhood is often a reason why many women 
may develop cancer before they decide to conceive [1, 2, 3, 4]. 
As the incidence of  malignant cancer increases with age, it affects 
an increasing number of  pregnant women as well as nulliparas 
[1, 2, 6, 7, 8]. Numerous women who suffered from cancer, 
not infrequently in childhood, often express their desire to bear 
children [2, 3, 4, 5, 6].
Moreover, the issue of  oncologic treatment applies to many 
young women who still have not made the decision about their 
possible motherhood. A study in over 1000 women diagnosed 
with cancer between the ages of  18 to 40 years showed that 
only under 60% of  them received information about the risk of  
treatment-related infertility from their oncologists, and only about 
5% were referred to a consult with a reproductive endocrinologist 
[9]. Needless to say, the decision about initiating fertility-sparing 
treatment should be established at the time of  diagnosis, before 
any oncologic treatment is started.
In 2012, over 10% of  female cancers diagnosed in the USA 
affected women of  childbearing age [7, 8]. The occurrence of  
cancer during pregnancy has been estimated at 1/1000 pregnant 
women globally. Premalignant cervical lesions, as well as 
cervical cancer and breast cancer, are among the most frequent 
malignancies detected during pregnancy, with melanomas and 
hematologic cancers as significantly less common [1]. Cervical 
cancer remains to be the most frequently diagnosed neoplasm 
of  the genital tract in women of  childbearing age [2, 3, 10, 11]. 
Approximately 20% of  cervical cancer patients are up to 40 years 
of  age, with early stage cervical cancer, i.e. carcinoma in situ and 
stage IA cancer, diagnosed in over 60% of  women in that age 
group [10]. The long and multi-step process of  carcinogenesis 
within the cervix, from CIN 1 to invasive cancer (often lasting 
for many years), the ability to observe the cervix, and two non- 
invasive diagnostic methods of  cytology and colposcopy allow 
to detect both, premalignant lesions and a large proportion of
cervical cancer in its preclinical stage (IA) and early clinical stage 
(IB1 with lesions of  <2cm in diameter). In these stages of  cervical 
cancer, when metastases are an unexpected occurrence and only 
isolated cancer cells are found in the lymph nodes, genital- 
sparing surgical treatment, i.e. surgical conization and vaginal 
radical trachelectomy with laparoscopic lymphadenectomy, may 
be implemented. The advantages of  such procedures have been 
reported by numerous authors [12,13,14]. In our research, 76.5% 
of  women after surgical conization achieved pregnancy and 90% 
delivered at term, whereas 50% of  women after vaginal radical 
trachelectomy with laparoscopic lymphadenectomy achieved 
pregnancy and 50% delivered at term. It should be emphasized 
that pregnancy after vaginal radical trachelectomy should be 
regarded as a high-risk pregnancy, with higher incidence of  
chorioamnionitis and preterm rupture of  membrane (PROM), 
often resulting in premature delivery. Some clinicians attempted 
to implement genital-sparing treatment in subj ects with more 
advanced cervical cancer, e.g. clinical stages IB2 and IIA, first 
using chemotherapy (platinum with paclitaxel), followed by 
conization or cervical amputation. However, in light of  oncologic 
effectiveness, this procedure seems risky [4].
As far as the other female genital tract neoplasms are 
concerned, reports (45 studies) about treatment options with 
progestogens in endometrial cancer limited to the mucous 
membrane, i.e. IA clinical stage advancement according to 
previous FIGO classification (1988), have been published. 
Notably, endometrial cancer during childbearing years is rare. 
Thus, data on progestogen treatment of  both, endometrial 
hyperplasia and stage I clinically advanced adenocarcinoma 
in women who wish to preserve fertility are extremely limited 
(approximately 300 cases) [15].
In our center, we observed 2 patients (aged 41 and 43 years), 
who wished for medroxyprogesterone to be introduced for 6 
months after curettage of  the uterine cavity. Control curettage
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with subsequent histology after this period of  time did not 
reveal any neoplastic processes but neither one of  them became 
pregnant.
Ovarian cancer in young women, even young girls, who 
wish to preserve fertility occurs much more frequently than 
endometrial cancer. In our study, a diagnosed and treated 
group of  26 young women (aged 18-29 years) with a unilateral, 
borderline malignancy ovarian cancer, as well as a group of  17 
young women (aged 16-23 years) with stage I clinically advanced 
invasive cancer also limited to one ovary, show possibility of  
organ-sparing surgical treatment with fertility preservation.
In all cases with a unilateral tumor of  borderline malignancy 
the procedure was as follows: after incision into the cavity, 
peritoneal lavage was performed and taken for cytological 
examination, unilateral salpingo-ooporectomy, random biopsy 
of  the second ovary for histologic examination, and inspection 
of  the pelvis minor and abdominal cavity. Neither cytological 
examination of  the lavage fluid nor histologic examination of  the 
biopsied samples in the second ovary showed any cancer cells.
Surgical treatment in the second group, with stage I clinically 
advanced invasive cancer of  one ovary (stage IA), consisted of  
peritoneal lavage taken for cytological examination, followed 
by unilateral salpingo-ooporectomy and tumor removal with the 
capsule intact without any damage, omentectomy, appendectomy, 
pelvic and paraaortic lymphadenectomy, and a random biopsy 
of  the second ovary for histologic examination. Definitive 
histological examination showed metastasis of  cancer cells to the 
lymph nodes (stage IIIA1) in only one case.
During the observation period of  2-7 years, there were no 
cases with any recurrence of  neoplastic process in either of  the 
two groups.
In the group with borderline malignancy, 19 women decided 
to become pregnant and 14 (73.7%) conceived and gave birth at 
term. In the group with stage I clinically advanced cancer, out of  
the 11 women who wanted to become pregnant shortly after the 
operation, 8 (72.7%) managed to conceive and deliver at term. 
Therefore, fertility-sparing surgical treatment of  ovarian cancer 
with both, borderline malignancy and stage IA invasiveness 
gives good results in terms of  subsequent procreation, what 
is consistent with reports of  other authors [16, 17]. In cases 
where fertility-sparing surgical treatment is implemented with 
subsequent chemotherapy, women who wish to preserve fertility 
should have oocytes or ovarian tissue sampled and frozen in 
designated centers prior to chemotherapy [16, 17].
Regardless of  the fact that breast cancer more frequently 
affects postmenopausal women, about 7% of  the cases are 
diagnosed under the age of  40, constituting about 40% of  all 
malignant cancers found in women of  childbearing age [18]. 
The decision to become pregnant after breast cancer treatment 
presents a great challenge, mainly due to the fact that many 
of  those cancers appear as the effect of  hormonal stimulation. 
Thus, alongside women who are optimistic about pregnancy after 
breast cancer treatment, there is a group of  patients who oppose 
pregnancy after cancer treatment or remain undecided [19].
Numerous analyses of  the existing data on the impact of  
pregnancy on cancer recurrence failed to demonstrate its negative 
consequences on disease relapse or recurrence. This statement is 
also true with regard to cancers that possess a hormonal receptor 
status or BRCA 1/2 mutation carrier status [18, 20, 21].
Also, the same authors believe that there is no reason to limit 
breastfeeding with the healthy breast after treatment completion. 
Moreover, breastfeeding is a protective factor against the 
development of breast cancer.
Independently of  tumor location, i.e. not only within the 
genitals but also in other parts of  the body, protective shields 
for the adnexa or laparoscopic relocation of  the ovaries (most 
frequently to the area of  paracolic gutters) should be done in 
women wishing to preserve their fertility if  radiotherapy is 
applied. The prognosis depends on changes in the vascularization 
of  the ovary and the degree of  radiation scatter. Sometimes both, 
the adnexa and the uterus should be shielded as radiation can lead 
to reduction of  the uterine mass, and is related to complications 
in future pregnancy.
Recent reports have confirmed previous, empirically 
employed, attempts of  preserving adnexal function from the 
undesirable effects of  chemotherapeutic drugs by using GnRH 
analogues [22, 23]. However, this method is characterized 
by limited effectiveness -  the estimated improvement in the 
function of  the ovaries does not exceed 10% (2013 ESMO 
recommendations) [1, 23].
In cases when none of  the aforementioned techniques can 
be used, or if  there is a reasonable suspicion of  a possible lack 
of  their effectiveness, the latest developments in the assisted 
reproductive technology may offer significant help. They include 
both, freezing the embryos and oocytes, as well as ovarian tissue 
fragments. Embryo freezing is the technique of  choice if  the 
affected woman has a partner with whom she plans to start a 
family. Currently, this method is fully approved and reimbursed 
by the Ministry of  Health. In cases when the woman does not have 
a partner with whom she wishes to have children, the solution 
is to freeze mature oocytes. Depending on patient age and the 
timeframe in which oncologic treatment should begin, the oocytes 
can be retrieved without initial stimulation, and their maturation 
guaranteed in laboratory settings (in vitro maturation -  IVM). 
However, this technique is associated with lower (estimated only 
at about 10%) effectiveness than retrieving the oocytes after the 
initial stimulation [7]. Significantly better results of  attaining 
pregnancy (estimated at about 30-35%) are achieved through 
the vitrification technique. In contrast to the previously used 
slow freezing, nowadays the mature oocytes in the M2 stage are 
rapidly frozen in liquid nitrogen [24]. The method that currently 
offers most promise involves freezing the entire fragments of  the 
ovarian tissue. Although this technique is still considered as an 
experimental method, to the best of  our knowledge, a few dozen 
cases achieving pregnancy in this method have been described 
so far, the initial results are promising and give a chance for 
offspring to 30% of  women who decide to choose this technique 
[25, 26].
Ultimately, it should be noted that cancer patients who wish 
to preserve fertility should be given comprehensive information 
about the safety of  reproductive organ-sparing techniques, as 
well as the possibility of  using other fertility-sparing methods 
before oncologic treatment commences. In cases of  early-stage 
cancer within the reproductive tract, the principles of  organ- 
sparing surgical treatment, as well as the risk of  potential cancer 
recurrence, should be discussed.
In cases of  cancers located elsewhere and requiring 
radiation and/or chemotherapy, the possibility of  shielding the
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reproductive organs against the undesired effects of  radiation 
or chemotherapeutic agents should be presented to the affected 
women. It should be noted that recent years have brought new 
methods of  reproductive medicine that offer hope for motherhood 
to those women in whom the previously described methods of  
preserving fertility cannot be applied.
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